Our CEO, Dr. Carmine Jabri, will be cohosting a webinar with Jan Flegeau, Director of Regulatory Affairs, to give an overview of what’s to come from the EU MDR.
Nitrosamine impurities continue to be a major focus for regulators—and in 2026, scrutiny is not slowing down.
